These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Nanotechnology as a promising strategy for alternative routes of insulin delivery. Reis CP; Damgé C Methods Enzymol; 2012; 508():271-94. PubMed ID: 22449931 [TBL] [Abstract][Full Text] [Related]
27. Oral colon-specific drug delivery of protein and peptide drugs. Sinha V; Singh A; Kumar RV; Singh S; Kumria R; Bhinge J Crit Rev Ther Drug Carrier Syst; 2007; 24(1):63-92. PubMed ID: 17430100 [TBL] [Abstract][Full Text] [Related]
28. A review of biodegradable polymeric systems for oral insulin delivery. Luo YY; Xiong XY; Tian Y; Li ZL; Gong YC; Li YP Drug Deliv; 2016 Jul; 23(6):1882-91. PubMed ID: 26066036 [TBL] [Abstract][Full Text] [Related]
29. Therapeutic nanosystems for oral administration of insulin. do Carmo FA; Sathler PC; Zancan P; Rodrigues CR; Castro HC; de Sousa VP; Sola-Penna M; Cabral LM Curr Pharm Biotechnol; 2014; 15(7):620-8. PubMed ID: 25219867 [TBL] [Abstract][Full Text] [Related]
30. Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus. Wong CY; Al-Salami H; Dass CR Int J Pharm; 2018 Oct; 549(1-2):201-217. PubMed ID: 30071309 [TBL] [Abstract][Full Text] [Related]
31. Alternative routes of insulin delivery. Krishnankutty RK; Mathew A; Sedimbi SK; Suryanarayan S; Sanjeevi CB Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 34(10):933-48. PubMed ID: 19893243 [TBL] [Abstract][Full Text] [Related]
32. New ways of insulin delivery. Heinemann L Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811 [TBL] [Abstract][Full Text] [Related]
33. Nanomedicine for treatment of diabetes in an aging population: state-of-the-art and future developments. Krol S; Ellis-Behnke R; Marchetti P Nanomedicine; 2012 Sep; 8 Suppl 1():S69-76. PubMed ID: 22640905 [TBL] [Abstract][Full Text] [Related]
34. Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists. Poudwal S; Misra A; Shende P J Drug Target; 2021 Sep; 29(8):834-847. PubMed ID: 33620269 [TBL] [Abstract][Full Text] [Related]
35. Nanoparticle strategies for the oral delivery of insulin. Damgé C; Reis CP; Maincent P Expert Opin Drug Deliv; 2008 Jan; 5(1):45-68. PubMed ID: 18095928 [TBL] [Abstract][Full Text] [Related]
36. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Chen MC; Sonaje K; Chen KJ; Sung HW Biomaterials; 2011 Dec; 32(36):9826-38. PubMed ID: 21925726 [TBL] [Abstract][Full Text] [Related]
37. Controlled release of biologics for the treatment of type 2 diabetes. Gilroy CA; Luginbuhl KM; Chilkoti A J Control Release; 2016 Oct; 240():151-164. PubMed ID: 26655062 [TBL] [Abstract][Full Text] [Related]
38. Oral peptide delivery: Translational challenges due to physiological effects. Tyagi P; Pechenov S; Anand Subramony J J Control Release; 2018 Oct; 287():167-176. PubMed ID: 30145135 [TBL] [Abstract][Full Text] [Related]
39. New ways of insulin delivery. Heinemann L Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662 [TBL] [Abstract][Full Text] [Related]
40. Liraglutide in oral antidiabetic drug combination therapy. Garber AJ Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]